Platin sensitivity and long-term survival in Stage III epithelial ovarian cancer patients

Purpose: The aim of the present study was to assess the effect of platin sensitivity on long-term survival of Stage III epithelial ovarian cancer (EOC) patients. Methods: The records of all histologically confirmed Stage HI EOC and PPC patients diagnosed during 19952006 were reviewed. A comparison of selected characteristics was made between long-term (> 5 years) and short-term (< 3 years) survivors. Results: Among 58 Stage III patients, 20 had long-term and 18 short-term survival. The rate of platin sensitive patients in long-term survivors was significantly higher than in short-term survivors (95.0% vs 27.8%, p < 0.001). The sensitivity and specificity of platin sensitivity for long-term survival was 95% and 72.2%, respectively, and the positive and negative predictive value was 79.2% and 92.8%, respectively. No statistically significant difference between the groups was found with regard to other selected characteristics. Conclusion: The rate of platin sensitive patients was significantly higher among long-term survivors than among short-term survivors but the specificity and positive predictive value of platin sensitivity for long-term survival prediction were relatively low precluding its practical clinical use.

Epithelial ovarian cancer; Platin sensitivity; Primary peritoneal carcinoma; Long-term survival; Short-term survival

[1] Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M.: “Cancer statistics, 2001”. CA Cancer J. Clin., 2001, 51, 15.

[2] Pisani P., Parkin D.M., Bray F., Ferlay J.: “Estimates of the worldwide mortality from 25 cancers in 1990”. Int. J. Cancer, 1999, 83, 18.

[3] Berkenblit A., Cannistra S.A.: “Advances in the management of epithelial ovarian cancer”. J. Reprod. Med., 2005, 50, 426.

[4] Eisenhauer E.A., Gore M., Neijt J.P.: “Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?”. Ann. Oncol., 1999, 10 (suppl. 1), S9.

[5]Ozols R.F.: “Systemic therapy for ovarian cancer: current status and new treatments”. Semin. Oncol., 2006, 33, S3.

[6] Barda G., Menczer J., Chetrit A., Lubin F., Beck D., Piura B. et al.: “Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study”. Am. J. Obstet. Gynecol., 2004, 190, 1039.

[7] Heintz A.P., Odicino F., Maisonneuve P., Beller U., Benedet J.L. et al.: “Carcinoma of the ovary”. Int. J. Gynaecol. Obstet., 2003, 83, S135.

[8] Agarwal R., Kaye S.B.: “Ovarian cancer: strategies for overcoming resistance to chemotherapy”. Nat. Rev. Cancer, 2003, 3, 502.

[9] Chan J.K., Cheung M.K., Husain A., Teng N.N., West D., Whittemore A.S. et al.: “Patterns and progress in ovarian cancer over 14 years”. Obstet. Gynecol., 2006, 108, 521.

[10] Rubin S.C., Randall T.C., Armstrong K.A., Chi D.S., Hoskins W.J.: “Ten year follow-up of ovarian cancer patients after secondlook laparotomy with negative findings”. Obstet. Gynecol., 1999, 93, 21.

[11] Colombo N., Van Gorp T., Parma G., Amant F., Gatta G., Sessa C., Vergote I.: “Ovarian cancer”. Crit. Rev. Oncol. Hematol., 2006, 60, 159.

[12] Lambert H.E., Gregory W.M., Nelstrop A.E., Rustin G.J.: “Longterm survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population”. Int. J. Gynecol. Cancer, 2004, 14, 772.

[13] Olsen C.M., Green A.C., Whiteman D.C., Sadeghi S., Kolahdooz F., Webb P.M.: “Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis”. Eur. J. Cancer, 2007, 43, 690.

[14] Hankinson S.E., Colditz G.A., Hunter D.J.,Willett W.C., Stampfer M.J., Rosner B. et al.: “A prospective study of reproductive factors and risk of epithelial ovarian cancer”. Cancer, 1995, 76, 284.

[15] Raspollini M.R., Amunni G., Villanucci A., Boddi V., Taddei G.L.: “COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer”. Acta Obstet. Gynecol. Scand., 2006, 85, 493.

[16] Cooper B.C., Sood A.K., Davis C.S., Ritchie J.M., Sorosky J.I., Anderson B. et al.: “Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer”. Obstet. Gynecol., 2002, 100, 59.

[17] Wikborn C., Pettersson F., Moberg P.J.: “Delay in diagnosis of epithelial ovarian cancer”. Int. J. Gynaecol. Obstet., 1996, 52, 263.

[18] Goff B.A., Mandel L., Muntz H.G., Melancon C.H.: “Ovarian carcinoma diagnosis”. Cancer, 2000, 89, 2068.

[19] Fruchter R.G., Boyce J.: “Delays in diagnosis and stage of disease in gynecologic cancer”. Cancer Detect Prev., 1981, 4, 481.

[20] Smith E.M., Anderson B.: “The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary”. Cancer, 1985, 56, 2727.

[21] Flam F., Einhorn N., Sjovall K.: “Symptomatology of ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1988, 27, 53.

[22] Kirwan J.M.J., Tincello D.G., Herod J.J.O., Frost O., Kingston R.E.: “Effect of delays in primary care referral on survival of women with epithelial ovarian cancer”. Br. Med. J., 2002, 324, 148.

[23] Lataifeh I., Marsden D.E., Robertson G., Gebski V., Hacker N.F.: “Presenting symptoms of epithelial ovarian cancer”. Aust. N Z J Obstet. Gynaecol., 2005, 45, 211.

[24] Kaern J., Aghmesheh M., Nesland J.M., Danielsen H.E., Sandstad B., Friedlander M., Trope C.: “Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?”. Int. J. Gynecol. Cancer, 2005, 15, 1014.

[25] Goff B.A., Muntz H.G., Greer B.E., Tamimi H.K., Gown A.M.: “Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer”. Obstet. Gynecol., 1998, 92, 88.

[26] Hunter R.W., Alexander N.D., Soutter W.P.: “Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?”. Am. J. Obstet. Gynecol., 1992, 166, 504.

[27] Spentzos D., Levine D.A., Ramoni M.F., Joseph M., Gu X., Boyd J. et al.: “Gene expression signature with independent prognostic significance in epithelial ovarian cancer”. J. Clin. Oncol., 2004, 22, 4700.